M-Series
M-Series

£69.99

Add to basket This product has multiple variants. The options may be chosen on the product page

M-Series

£69.99

  • UK Stock
  • Secure Payments
  • Discreet UK Delivery

M-Series contains mazdutide research material, a synthetic peptide studied for dual GLP-1 and glucagon receptor activity. Supplied as a 10mg lyophilised research vial. Not for human or veterinary use.

COMPLETE YOUR KIT

Bacteriostatic Water - 3ml
Bacteriostatic Water - 3ml

In stock

£3.99
1 Vial
£69.99
1 Vial
£62.99 Save 10%
3 Vials
£59.49 Save 15%
5 Vials
£55.99 Save 20%

For in vitro laboratory research only.
Not for human or veterinary use. Not for diagnosis, treatment, cure, or prevention of any disease. No dosage, administration, or injection guidance is provided.

M-Series is the Havoc Labs product name for mazdutide research material. Mazdutide, also identified as IBI362 or LY3305677, is a synthetic peptide analogue of oxyntomodulin studied for dual GLP-1 and glucagon receptor activity.

Research material only
This material is not supplied as a medicine, treatment, supplement or consumer product. It is not for human or veterinary use, consumption or administration, and is not intended to diagnose, treat, cure or prevent any disease.

Compound overview

Reference compoundMazdutide
Research identifiersIBI362; LY3305677
Compound classSynthetic oxyntomodulin analogue
Receptor targetsGLP-1 receptor and glucagon receptor
CAS reference2259884-03-0
Supplied formLyophilised research material; 10mg vial

Research context

Mazdutide is a dual receptor agonist, distinct from GLP-1-only peptides and from compounds combining GLP-1, GIP and glucagon receptor activity. Published research includes controlled studies of metabolic endpoints in defined clinical populations.

Clinical publications describe specific trial formulations, participant groups and monitored conditions. They do not demonstrate equivalence to a Havoc Labs research vial or establish the suitability of this material for human use. Findings and adverse events must be interpreted together; see the Research tab for linked study summaries.

Reference identifiers are not batch verification. Consult the matching analytical documentation for identity, purity and the chemical form supplied. No pharmaceutical formulation, sterility or clinical equivalence is implied by the product name.

Batch documentation

Independent analytical documentation is published where available for specific batches and variations. A result indicator appears only when a published record is available. Match the compound, vial size and batch identifier to the corresponding report before relying on any result.

Supply and laboratory handling

  • Supplied as a 10mg vial of lyophilised research material.
  • Keep the vial sealed and protected from moisture, heat and direct light.
  • Use suitable laboratory controls and independently verify identity and concentration for the intended experimental model.
  • Follow batch-specific storage and handling instructions where supplied.

Frequently asked questions

What is M-Series?

The Havoc Labs product name for mazdutide research material. Published literature also uses IBI362 and LY3305677.

Which receptors are studied?

Mazdutide is studied as a dual GLP-1 and glucagon receptor agonist. It is not a GIP/GLP-1/glucagon triple agonist.

Are clinical trials available?

Yes. The Research tab links controlled trials and identifies their populations and limitations. Trial results concern the study materials, not this research batch.

Is this a pharmaceutical product?

No. This page supplies laboratory research material, not the clinical formulations described in published trials.

Are laboratory results available?

A shield appears beside a variation only when a published result is available. Check the COA tab for matching records; no indicator means no product-specific result is currently displayed.

How should the material be stored?

See the Storage Guidelines tab and follow any batch-specific instructions. No human dosing, administration or injection guidance is provided.

Information reviewed 27 September 2026. Reference sources: Ji et al., 2023 (compound and clinical research context) and PubChem reference identifiers.

Size

10mg

Batch-specific analytical documentation

Independent analytical results are published for selected Havoc Labs products, vial sizes and batches. The result attached to one variation must not be treated as evidence for a different size or batch.

  • Result available: a published report is available for the marked variation.
  • Test pending: a sample has been submitted, but no completed result is being claimed.
  • No indicator: no product-specific result is currently displayed for that variation.

Check the identifiers

Always match the compound, vial size and batch reference on the product to the corresponding laboratory record. Where the laboratory provides an independent verification facility, use it to confirm the report.

Browse published lab results →

Storage and stability

Storage requirements can vary by compound, physical form, intended storage duration and batch. Follow the lot-specific documentation and your laboratory’s validated procedure wherever these are available.

Form Suggested storage Important note
Sealed lyophilised material Keep in a cool, dry place, refrigerated at 2–8°C or frozen, as appropriate for the compound and intended storage period. Keep sealed, dry and protected from direct light. Follow compound- and batch-specific documentation and avoid repeated temperature cycling.
Reconstituted solution Refrigerate at 2–8°C unless the applicable laboratory protocol specifies otherwise. Stability depends on the preparation conditions, solvent, concentration, container and handling. No universal storage period is claimed.

No universal shelf-life is claimed

Do not assume a fixed expiry or prepared-solution storage period unless it is supported by relevant stability data or batch documentation. Where a lot-specific document gives different instructions, that document takes precedence.

Published research

The publications below concern mazdutide (IBI362 / LY3305677) in defined clinical study settings. They describe trial formulations and monitored populations, not the Havoc Labs M-Series research batch. Clinical findings do not authorise human use of this material.

  1. Ji L et al.; GLORY-1 Investigators. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. New England Journal of Medicine, 2025;392(22):2215–2225. Phase 3, double-blind, placebo-controlled trial involving 610 adults over 48 weeks. Reported greater body-weight reduction and changes in cardiometabolic measures with mazdutide. Gastrointestinal adverse events were most common. Results apply to the studied population, formulation and protocol. DOI: 10.1056/NEJMoa2411528. View on PubMed ↗
  2. Ji L et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nature Communications, 2023;14:8289. Double-blind, placebo-controlled study over 24 weeks, with 248 participants. Evaluated body-weight change and cardiometabolic endpoints; reported greater weight reduction with mazdutide. A limited-duration clinical trial, not batch evidence or assurance of long-term safety. DOI: 10.1038/s41467-023-44067-4. View on PubMed ↗
  3. Zhang B et al. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial. Diabetes Care, 2024;47(1):160–168. Study in 250 adults over 20 weeks, including placebo and an open-label dulaglutide comparator. Evaluated HbA1c and body-weight changes. Reported glucose-related improvements alongside adverse events, including gastrointestinal symptoms. Does not establish suitability of research material for diabetes treatment. DOI: 10.2337/dc23-1287. View on PubMed ↗
  4. Hsia SH et al. Mazdutide in adults with obesity or overweight: a US multicentre phase 2 placebo-controlled trial. The Lancet Diabetes & Endocrinology, 2026; published online 21 August. Randomised study of 179 adults without type 2 diabetes at 24 US centres, with treatment over 48 weeks. Reported body-weight reduction; gastrointestinal events and treatment discontinuations varied across study groups. Limited sample size and duration constrain conclusions about uncommon or longer-term harms. DOI: 10.1016/S2213-8587(26)00160-9. View on PubMed ↗

Literature is not batch evidence

The cited studies do not establish the identity, purity, sterility, performance or clinical equivalence of a Havoc Labs batch. Match the compound, vial size and batch identifier against the applicable analytical documentation. No dosing, administration or injection guidance is provided.

References reviewed 27 September 2026.